clinical trial · NCT06568094
A Study of HRS-5041 Tablets Combined With Antitumor Therapy in Subjects With Advanced Prostate Cancer
Jiangsu HengRui Medicine Co., Ltd.·phase2·recruiting·n = 100
Prostate CancerHRS-5041 tabletsAbiraterone Acetate tablets（II）Prednisone Acetate tabletsDocetaxel InjectionHRS-1167 tabletsSHR2554 tabletsHRS-6208 capsulesDarolutamide Tablets
brief summary
The purpose of this study is to evaluate the efficacy, and safety of HRS-5041 tablets combined with antitumor therapy in subjects with advanced prostate cancer.
started
Sep 25, 2024
primary completion
Jun 1, 2026
completion
Jun 1, 2027
last updated
Jun 10, 2026
official title
An Open, Multicenter Phase Ib/II Study on the Safety, Tolerability and Efficacy of HRS-5041 Tablets Combined With Antitumor Therapy in Subjects With Advanced Prostate Cancer
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol